Download PDF
Exp Clin Endocrinol Diabetes 2014; 122(08): 484-490
DOI: 10.1055/s-0034-1372594
Article
© J. A. Barth Verlag in Georg Thieme Verlag KG Stuttgart · New York

Markers of the Progression of Complications in Patients with Type 2 Diabetes: A One-year Longitudinal Study

M. C. Preciado-Puga
1   Departmente of Medical Science, Division of Health Science, University of Guanajuato, Campus León
,
J. M. Malacara
1   Departmente of Medical Science, Division of Health Science, University of Guanajuato, Campus León
,
M. E. Fajardo-Araujo
1   Departmente of Medical Science, Division of Health Science, University of Guanajuato, Campus León
,
K. Wröbel
2   Department of Chemistry, University of Guanajuato, Campus Guanajuato
,
K. Wröbel
2   Department of Chemistry, University of Guanajuato, Campus Guanajuato
,
C. Kornhauser-Araujo
1   Departmente of Medical Science, Division of Health Science, University of Guanajuato, Campus León
,
M. E. Garay-Sevilla
1   Departmente of Medical Science, Division of Health Science, University of Guanajuato, Campus León
› Author Affiliations
Further Information

Publication History

received 13 December 2013
first decision 19 March 2014

accepted 20 March 2014

Publication Date:
17 September 2014 (online)

Also available at
    Permissions and Reprints

Abstract

Hyperglycemia induces tissue damage and complications by mechanisms that produce advanced glycation end-products (AGEs) and inflammation.

Aims:

To investigate the factors associated with the progression of complications in Type 2 diabetes patients.

Materials and Methods:

We recruited 157 patients (110 women and 47 men) with diabetes for more than 5 years who were non-smokers and did not have current infections or chronic diseases. Patients were grouped according to neuropathy, nephropathy, and retinopathy status: without (I), slight or moderate (II), and severe complications (III). We measured glucose, lipids and HbA1c, low molecular weight AGEs (LMW AGEs), high sensitivity C-reactive protein (CRP), TNF-α, IL-6, and malondialdehyde (MDA). Patients were re-evaluated 1 year later.

Results:

Patients were 52.2±6.8 years old with 11.0±4.9 years since diagnosis. After 1 year, circulating AGEs increased (p<0.0001) and eGFR decreased (p<0.0007) in groups II and III. IL-6 and MDA decreased in groups I and II. CRP (p<0.029) and AGEs (p<0.0001) increased in group II. At baseline in group I, TNF-α levels were higher (p<0.002) in patients who later developed complications. In group II, TNF-α levels (p<0.015) and microalbuminuria (p<0.00004) were higher in patients whose complications progressed. Logistic regression analysis showed that complication progress was significantly associated with log(albuminuria) (p<0.004) and log(TNF-α) (p<0.008). In the total group, AGEs were associated with age (p<0.024) and HbA1c (p<0.026).

Conclusions:

Our results suggest that baseline TNF-α is an important predictor of complication progression in Type 2 diabetes patients. AGEs also increased during the deterioration of renal function after 1 year of follow-up observation.

Key words

diabetes - advanced glycation end products - TNF-α
 

  • References

  • 1 Nathan DM, Clearly PA, Backlund JY et al. Intensive Diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Eng J Med 2005; 353: 2643-2653
    CrossrefPubMedGoogle Scholar
  • 2 Holman RR, Paul SK, Bethel MA et al. 10 years follow-up of intensive glucose control in type 2diabetes. N Engl J Med 2008; 359: 1577-1589
    CrossrefPubMedGoogle Scholar
  • 3 Aronson D, Rayfield EJ. How hyperglycemia promotes atherosclerosis: molecular mechanisms. Cardiovasc Diabetol 2002; 8: 1-10
    PubMedGoogle Scholar
  • 4 Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature 2001; 414: 813-820
    CrossrefPubMedGoogle Scholar
  • 5 Méndez JD, Xie J, Aguilar-Hernández M et al. Trends in advanced glycation end products research in diabetes mellitus and its complications. Mol Cell Biochem 2010; 341: 33-41
    CrossrefPubMedGoogle Scholar
  • 6 Sharp PS, Rainbow S, Mukherjee S. Serum levels of low molecular weight advanced glycation end products in diabetic subjects. Diabetes UK 2003; 20: 575-579
    PubMedGoogle Scholar
  • 7 Weiss MF, Erhard P, Kader-Attia FA et al. Mechanisms for the formation of glycoxidation products in end-stage renal disease. Kidney Int 2000; 57: 2571-2585
    CrossrefPubMedGoogle Scholar
  • 8 Luevano-Contreras C, Garay-Sevilla ME, Chapman-Novakofski K. Role of dietary advanced glycation end products in diabetes mellitus. J of Evidence-Based complementary & Alternative Medicine 2013; 18: 50-66
    PubMedGoogle Scholar
  • 9 Fernández-Real JM, Ricart W. Insulin resistance and chronic cardiovascular inflammatory syndrome. Endocrine Reviews 2003; 24: 278-301
    CrossrefPubMedGoogle Scholar
  • 10 Garay-Sevilla ME, Regalado JC, Wróbel-Zasada K et al. Advanced glycosylation end products in skin, serum, saliva and urine and its association with complications of patients with type 2 diabetes mellitus. J Endocrinol Invest 2005; 28: 223-230
    CrossrefPubMedGoogle Scholar
  • 11 Cai W, Gao QD, Zhu L et al. Oxidative stress-inducing carbonyl compounds from common foods: novel mediators of cellular dysfunction. Mol Med 2002; 8: 337-346
    PubMedGoogle Scholar
  • 12 Vlassara H, Cai W, Crandall J et al. Inflammatory mediators are induced by dietary glycotoxins, a major risk factor for diabetic angiopathy. Proc Natl Acad Sci USA 2002; 26; 99: 15596-15601
    CrossrefPubMedGoogle Scholar
  • 13 Tan KC, Chow WS, Tam S et al. Association between acute-phase reactants and advanced glycation end products in type 2 diabetes. Diabetes Care 2004; 27: 223-228
    CrossrefPubMedGoogle Scholar
  • 14 Levey AS, Bosch JP, Lewis JB et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999; 130: 461-470
    CrossrefPubMedGoogle Scholar
  • 15 National Kidney Foundation . K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002; 39 (Suppl. 01) S1-S266
    PubMedGoogle Scholar
  • 16 Sergio B, Charles G. Retinopatía Diabética. Harcourt Brace 1998: 63-89
    PubMedGoogle Scholar
  • 17 Feldman EL, Stevens MJ, Thomas PK et al. A practical two step quantitative clinical and electrophysiological assessment for the diagnosis and staging of diabetic neuropathy. Diabetes Care 1994; 17: 1281-1289
    CrossrefPubMedGoogle Scholar
  • 18 Wróbel K, Wróbel K, Garay-Sevilla ME et al. Novel analytical approach to monitoring advanced glycosylation end products in human serum with online spectrophotometric and spectrofluorimetric detection in flow system. Clin Chem 1997; 43: 1563-1569
    PubMedGoogle Scholar
  • 19 Serafín-Muñoz AH, Preciado-Puga M, Wrobel K et al. Microassay for malondialdehyde in human serum by extraction spectrophotometry Using an internal standard. Microchim Acta 2004; 148: 285-291
    CrossrefPubMedGoogle Scholar
  • 20 The Diabetes Control and Complications Trial Research Group . The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 977-986
    CrossrefPubMedGoogle Scholar
  • 21 Aronson D, Rayfield EJ. How hyperglycemia promotes atherosclerosis: molecular mechanism. Cardiovasc Diabetol 2002; 1: 1-10
    CrossrefPubMedGoogle Scholar
  • 22 Ramasamy R, Yan SF, Schmidt AM. Receptor for AGE (RAGE): signaling mechanisms in the pathogenesis of diabetes and its complications. Ann N Y Acad Sci 2011; 1243: 88-102
    CrossrefPubMedGoogle Scholar
  • 23 Sheetz MJ, King GL. Molecular understanding of hyperglycemia’s adverse effects for diabetic complications. JAMA 2002; 27; 288: 2579-2588
    CrossrefPubMedGoogle Scholar
  • 24 Semba RD, Fink JC, Sun K et al. Carboxymethyl-lysine, an advanced glycation end product, anddecline of renal function in older community-dwelling adults. EurJ Nutr 2009; 48: 38-44
    PubMedGoogle Scholar
  • 25 Simm A, Wagner J, Gursinsky T et al. Advanced Glycation end products: a biomarker for age as an outcome predictor after cardiac surgery?. Exp Gerontol 2007; 42: 668-675
    CrossrefPubMedGoogle Scholar
  • 26 Uribarri J, Cai W, Peppa M et al. Circulating glycotoxins and dietary advanced glycation end products: two links to inflammatory response, oxidative stress, and aging. J Gerontol A Biol Sci Med Sci 2007; 62: 427-433
    CrossrefPubMedGoogle Scholar
  • 27 De La Maza MP, Bravo A, Leiva L et al. Urinary excretion of fluorescent advanced glycation end products (ages) in the elderly. J Nutr Health Aging 2008; 12: 222-224
    CrossrefPubMedGoogle Scholar
  • 28 Suryawanshi NP, Bhutey AK, Nagdeote AN et al. Study of lipid peroxide and lipid profile in diabetes mellitus. Indian J Clin Biochem 2006; 21: 126-130
    CrossrefPubMedGoogle Scholar
  • 29 Akila VP, Harishchandra H, D’souza V et al. Age related changes in lipid peroxidation and antioxidants in elderly people. Indian J Clin Biochem 2007; 22: 131-134
    CrossrefPubMedGoogle Scholar
  • 30 Li JT, Hou FF, Guo ZJ et al. Advanced glycation end products upregulate C-reactive protein synthesis by human hepatocytes through stimulation of monocyte IL-6 and IL-1 beta production. Scand J Immunol 2007; 66: 555-562
    CrossrefPubMedGoogle Scholar
  • 31 Crasto CL, Semba RD, Sun K et al. Endogenous secretory receptor for advanced glycation end products is associated with low serum interleukin-1 receptor antagonist and elevated IL-6 in older community-dwelling adults. J Gerontol A Biol Sci Med Sci 2011; 66: 437-443
    PubMedGoogle Scholar
  • 32 Kilhovd BK, Giardino I, Torjesen PA et al. Increased serum levels of the specific AGE-compound methylglyoxal-derived hydroimidazolone in patients with type 2 diabetes. Metabolism 2003; 52: 163-167
    CrossrefPubMedGoogle Scholar
  • 33 Makita Z, Vlassara H, Cerami A et al. Immunochemical detection of advanced glycosylation end products in vivo. J Biol Chem 1992; 15: 5133-5138
    PubMedGoogle Scholar
  • 34 Sebeková K, Podracká L, Blazícek P et al. Plasma levels of advanced glycation end products in children with renal disease. Pediatr Nephrol 2001; 16: 1105-1112
    CrossrefPubMedGoogle Scholar
  • 35 Thomas MC, Tsalamandris C, MacIsaac R et al. Low-molecular-weight AGEs are associated with GFR and anemia in patients with type 2 diabetes. Kidney Int 2004; 66: 1167-1172
    CrossrefPubMedGoogle Scholar
  • 36 Thornalley PJ, Battah S, Ahmed N et al. Quantitative screening of advanced glycation endproducts in cellular and extracellular proteins by tandem mass spectrometry. Biochen J 2003; 375: 581-592
    PubMedGoogle Scholar